{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:05:01Z","timestamp":1790802301470,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bulcan.2018.12.001","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T18:39:08Z","timestamp":1547750348000},"page":"S102-S109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S","title":["Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l\u2019adulte et l\u2019enfant\u00a0: recommandation de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"106","author":[{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Borel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Hadhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-2693","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Naudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ouach\u00e9e-Chardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Platon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Roth-Guepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2018.12.001_bib0245","first-page":"93","article-title":"Chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0250","first-page":"62","article-title":"Beginning the CAR-T cell therapy revolution in the US and EU","volume":"66","author":"Grupp","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0255","first-page":"35","article-title":"CAR-T cells: a John von Neumann legacy?","volume":"66","author":"Quesnel","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0260","first-page":"43","article-title":"Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma","volume":"66","author":"Ghobadi","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0265","first-page":"39","article-title":"CRISPR\/Cas9 genome editing: fueling the revolution in cancer immunotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0270","first-page":"53","article-title":"Celyad's novel CAR-T cell therapy for solid malignancies","volume":"66","author":"Lonez","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0275","first-page":"37","article-title":"Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia","volume":"66","author":"Prommersberger","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0280","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0285","first-page":"59","article-title":"Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations","volume":"66","author":"Chabannon","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0290","first-page":"57","article-title":"Clinical units to set up chimeric antigen receptor T cell therapy (CAR-T cells): based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"66","author":"Yakoub-Agha","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"12S","key":"10.1016\/j.bulcan.2018.12.001_bib0295","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.bulcan.2017.10.017","article-title":"[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T cell therapy (CAR-T cells): guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"104","author":"Yakoub-Agha","year":"2017","journal-title":"Bull Cancer"},{"issue":"26","key":"10.1016\/j.bulcan.2018.12.001_bib0300","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2018.12.001_bib0305","first-page":"e158","article-title":"Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.12.001_bib0310","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2018.04.010","article-title":"Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome","volume":"24","author":"Raj","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2018.12.001_bib0315","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hon.2481","article-title":"Tocilizumab for severe cytokine release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B cell lymphoma","volume":"36","author":"Ureshino","year":"2017","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2018.12.001_bib0320","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.12.001_bib0325","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.12.001_bib0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T cell therapy\u00a0\u2013\u00a0assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.12.001_bib0335","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine release syndrome and neurotoxicity due to CAR-T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bulcan.2018.12.001_bib0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR-T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.bulcan.2018.12.001_bib0345","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2018.12.001_bib0350","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"224","key":"10.1016\/j.bulcan.2018.12.001_bib0355","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.bulcan.2018.12.001_bib0360","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"9967","key":"10.1016\/j.bulcan.2018.12.001_bib0365","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.bulcan.2018.12.001_bib0370","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bulcan.2018.12.001_bib0375","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2018.12.001_bib0380","article-title":"Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL)","author":"Frey","year":"2016","journal-title":"ASCO Abstract"},{"key":"10.1016\/j.bulcan.2018.12.001_bib0385","article-title":"Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes","author":"Turtle","year":"2015","journal-title":"ASH Abstract"},{"issue":"11S","key":"10.1016\/j.bulcan.2018.12.001_bib0390","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"26","key":"10.1016\/j.bulcan.2018.12.001_bib0395","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR-T cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2018.12.001_bib0400","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR-T cell therapy in patients with B cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bulcan.2018.12.001_bib0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"131","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0410","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"11S","key":"10.1016\/j.bulcan.2018.12.001_bib0415","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/j.bulcan.2016.09.008","article-title":"[Transfer of allogeneic stem cell transplant recipients to the intensive care unit: guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)]","volume":"103","author":"Moreau","year":"2016","journal-title":"Bull Cancer"},{"issue":"13","key":"10.1016\/j.bulcan.2018.12.001_bib0420","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.bulcan.2018.12.001_bib0425","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR-T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2018.12.001_bib0430","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bulcan.2018.12.001_bib0435","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/CCM.0000000000002425","article-title":"American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock","volume":"45","author":"Davis","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bulcan.2018.12.001_bib0440","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","author":"Mahadeo","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2018.12.001_bib0445","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.bulcan.2018.12.001_bib0450","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/CJI.0000000000000243","article-title":"Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T cell therapy","volume":"41","author":"Liu","year":"2018","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.bulcan.2018.12.001_bib0455","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2018.12.001_bib0460","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B cell malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bulcan.2018.12.001_bib0465","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"26","key":"10.1016\/j.bulcan.2018.12.001_bib0470","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR-T cell therapy in refractory large B cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.12.001_bib0475","series-title":"FDA briefing document oncologic drugs advisory committee meeting. BLA 125646. Tisagenlecleucel","author":"FDA","year":"2018"},{"issue":"5","key":"10.1016\/j.bulcan.2018.12.001_bib0480","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:30:39Z","timestamp":1757791839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118303692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0007455118303692"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.12.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l\u2019adulte et l\u2019enfant\u00a0: recommandation de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}